Phase II study of nimustine in metastatic soft tissue sarcoma

D. J Th Wagener; R. Somers; A. Santoro; J. Verweij; P. J. Woll; G. Blackledge; H. J. Schütte; M. A. Lentz; M. van Glabbeke

doi:10.1016/0277-5379(91)90424-C

Phase II study of nimustine in metastatic soft tissue sarcoma

D. J Th Wagener, R. Somers, A. Santoro, J. Verweij, P. J. Woll, G. Blackledge, H. J. Schütte, M. A. Lentz, M. van Glabbeke

Istituto Clinico Humanitas

Research output: Contribution to journal › Article

Abstract

The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m² every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.

Original language	English
Pages (from-to)	1604-1605
Number of pages	2
Journal	European Journal of Cancer and Clinical Oncology
Volume	27
Issue number	12
DOIs	https://doi.org/10.1016/0277-5379(91)90424-C
Publication status	Published - 1991

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/0277-5379(91)90424-C

Fingerprint Dive into the research topics of 'Phase II study of nimustine in metastatic soft tissue sarcoma'. Together they form a unique fingerprint.

Cite this

Wagener, D. J. T., Somers, R., Santoro, A., Verweij, J., Woll, P. J., Blackledge, G., Schütte, H. J., Lentz, M. A., & van Glabbeke, M. (1991). Phase II study of nimustine in metastatic soft tissue sarcoma. European Journal of Cancer and Clinical Oncology, 27(12), 1604-1605. https://doi.org/10.1016/0277-5379(91)90424-C

@article{ea7b7eb2c91b454da2b2acb7b56c7fba,

title = "Phase II study of nimustine in metastatic soft tissue sarcoma",

abstract = "The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.",

author = "Wagener, {D. J Th} and R. Somers and A. Santoro and J. Verweij and Woll, {P. J.} and G. Blackledge and Sch{\"u}tte, {H. J.} and Lentz, {M. A.} and {van Glabbeke}, M.",

year = "1991",

doi = "10.1016/0277-5379(91)90424-C",

language = "English",

volume = "27",

pages = "1604--1605",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

number = "12",

}

TY - JOUR

T1 - Phase II study of nimustine in metastatic soft tissue sarcoma

AU - Wagener, D. J Th

AU - Somers, R.

AU - Santoro, A.

AU - Verweij, J.

AU - Woll, P. J.

AU - Blackledge, G.

AU - Schütte, H. J.

AU - Lentz, M. A.

AU - van Glabbeke, M.

PY - 1991

Y1 - 1991

N2 - The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.

AB - The EORTC Soft Tissue and Bone Sarcoma Group has conducted a phase II trial in 33 eligible patients with metastatic soft tissue sarcoma with nimustine 100 mg/m2 every 6 weeks. In 31 evaluable patients there were 3 (10%) partial responses lasting 4.5,6 and 7.5 months, and 5 cases of stable disease. 12 patients had progressive disease and 11 patients early progressive disease. Toxicity consisted mainly of leukopenia and thrombocytopenia and nausea and vomiting. It is concluded that nimustine has only minor activity in soft tissue sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0026345861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026345861&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90424-C

DO - 10.1016/0277-5379(91)90424-C

M3 - Article

C2 - 1782068

AN - SCOPUS:0026345861

VL - 27

SP - 1604

EP - 1605

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 12

ER -